The cumulative incidence of CRC mortality was significantly higher for variant vs wild-type KRAS among patients with YO cancer (Gray test P = .02) (Figure 2A) and LO (Gray test P < .001) (Figure 2B). This evidence concerns the gene KRAS and colorectal carcinoma.